Bone Biologics (BBLG) Projected to Post Earnings on Monday

Bone Biologics (NASDAQ:BBLG) is anticipated to post its results after the market closes on Monday, May 11th. Analysts expect Bone Biologics to post earnings of ($0.54) per share for the quarter.

Bone Biologics (NASDAQ:BBLG) last released its quarterly earnings data on Monday, March 2nd. The company reported ($0.34) earnings per share (EPS) for the quarter, hitting analysts’ consensus estimates of ($0.34). On average, analysts expect Bone Biologics to post $-2 EPS for the current fiscal year and $-2 EPS for the next fiscal year.

Bone Biologics Trading Up 2.8%

BBLG stock traded up $0.04 during trading on Monday, reaching $1.35. 880 shares of the stock were exchanged, compared to its average volume of 21,372. The firm’s 50 day moving average is $1.24 and its 200 day moving average is $1.56. Bone Biologics has a twelve month low of $1.05 and a twelve month high of $6.75. The firm has a market cap of $2.43 million, a P/E ratio of -0.36 and a beta of 0.89.

Analyst Upgrades and Downgrades

Separately, Weiss Ratings raised shares of Bone Biologics from a “sell (e)” rating to a “sell (e+)” rating in a research report on Monday, April 27th. One equities research analyst has rated the stock with a Sell rating, According to data from MarketBeat.com, the company presently has a consensus rating of “Sell”.

Institutional Trading of Bone Biologics

A hedge fund recently raised its stake in Bone Biologics stock. DRW Securities LLC lifted its holdings in Bone Biologics Corp. (NASDAQ:BBLG) by 113.8% in the fourth quarter, according to the company in its most recent filing with the SEC. The fund owned 23,576 shares of the company’s stock after acquiring an additional 12,549 shares during the quarter. DRW Securities LLC owned 1.31% of Bone Biologics worth $34,000 at the end of the most recent quarter. Hedge funds and other institutional investors own 34.30% of the company’s stock.

Bone Biologics Company Profile

Bone Biologics, Inc (NASDAQ: BBLG) is a clinical-stage biotechnology company focused on the development of cell-based therapies for skeletal repair and regeneration. The company’s research efforts center on both allogeneic and autologous mesenchymal cell platforms designed to enhance bone healing in patients with orthopedic injuries and degenerative bone conditions. Its approach aims to provide alternatives to traditional grafting procedures by harnessing the regenerative potential of specialized stem cells.

Leveraging proprietary cell expansion and delivery technologies, Bone Biologics is advancing a pipeline of investigational therapies targeting indications such as spinal fusion, long-bone non-union and maxillofacial defects.